Drug prices and incentives to innovation by the pharmaceutical industry

Pharmaceutical Prices in the 21st Century

Volumn , Issue , 2015, Pages 389-401

  Levaggi, Rosella ^a   Pertile, Paolo ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943396525     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-12169-7_21     Document Type: Chapter

References (32)

1. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuoliene K, Haycox A, Garattini S, Gustafsson L (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 10(1):153, ISSN 1472- 6963. doi:10.1186/1472-6963-10-153. http://www.biomedcentral.com/1472-6963/10/153
2. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K (2009) Searching for cost effectiveness thresholds in the NHS. Health Policy 91(3):239-245, ISSN 0168-8510. doi:http://dx. doi.org/10.1016/j.healthpol.2008.12.010. http://www.sciencedirect.com/science/article/pii/S0168851008002911
3. Barigozzi F, Levaggi R (2008) Emotions in physician agency. Health Policy 88(1):1-14
4. Barros PP (2011) The simple economics of risk sharing agreements between the NHS and the pharmaceutical industry. Health Econ 20(4):461-470
5. Barros PP, Levaggi R (2011) Searching for approval: risk sharing as price discount? Mimeo
6. Capri S, Levaggi R (2007) International price regulations in the pharmaceutical sector: a common model to sharing cost and benefits. J Pharmaceut Finance Econ Pol 15(2):21-40
7. Carone G, Schwierz C, Xavier A (2012) Cost-containment policies in public pharmaceutical spending in the EU. Technical report, European Commission-Economic and Financial Affairs
8. Cook J, Vernon J, Mannin R (2008) Pharmaceutical risk-sharing agreements. Pharmacoeconomics 26:551-556. doi:10.2165/00019053-200826070-00002
9. Danzon PM, Chao L-W (2000) Does regulation drive out competition in pharmaceutical markets? J Law Econ 43(2):311-357
10. Danzon P, Towse A, Mestre-Ferrandiz J (2013) Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. doi:10.1002/hec.3021
11. De Pouvourville G (2006) Risk-sharing agreements for innovative drugs. Eur J Health Econ 7:155-157, ISSN 1618-7598. http://dx.doi.org/10.1007/s10198-006-0386-6.10.1007/s10198- 006-0386-6
12. Dickson M, Redwood H (1998) Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics 14(5):471-479, http://www.ingentaconnect.com/content/adis/pec/1998/00000014/00000005/art00002
13. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151-185, http://ideas.repec.org/a/eee/jhecon/v22y2003i2p151-185.html
14. Dulleck U, Kerschbamer R (2006) On doctors, mechanics, and computer specialists: the economics of credence goods. J Econ Lit 44(1):5-42
15. Filson D (2012) A Markov-perfect equilibrium model of the impacts of price controls on the performance of the pharmaceutical industry. RAND J Econ 43(1):110-138
16. Gravelle HSE (1998) Ex post value reimbursement for pharmaceuticals. Med Decis Making 18(2): S27-S38. doi:10.1177/0272989X9801800206. http://mdm.sagepub.com/content/18/2/S27. abstract
17. Griffin SC, Claxton KP, Palmer SJ, Sculpher MJ (2011) Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ 20(2):212-224, ISSN 1099-1050. doi:10.1002/hec.1586
18. Jena AB, Philipson T (2008) Cost-effectiveness analysis and innovation. J Health Econ 27 (5):1224-1236
19. Jena A, Philipson T (2009) Endogenous cost-effectiveness analysis in health care technology adoption. Working paper 15032, National Bureau of Economic Research, June 2009
20. Lakdawalla D, Sood N (2009) Innovation and the welfare effects of public drug insurance. J Public Econ 93(3-4):541-548
21. Levaggi R (2014) Pricing schemes for new drugs: a welfare analysis. Soc Sci Med 102:69-73, ISSN 0277-9536. doi:http://dx.doi.org/10.1016/j.socscimed.2013.11.048. http://www. sciencedirect.com/science/article/pii/S0277953613006606
22. Levaggi R, Moretto M, Pertile P (2013) The dynamics of pharmaceutical regulation and R&D investments. Working papers 13/2013, Department of Economics, University of Verona, Aug 2013. http://ideas.repec.org/p/ver/wpaper/13-2013.html
23. Loeb M, Magat WA (1979) A decentralized method for utility regulation. J Law Econ 22(2):399- 404, ISSN 00222186. http://www.jstor.org/stable/725125
24. NICE (2007) Final appraisal determination bortezomib monotherapy for relapsed multiple myeloma. Accessed 3 Mar 2010
25. OECD (2011) Health at a glance 2011: OECD indicators. Technical report, OECD
26. OECD (2013) Health at a glance 2013: OECD indicators. OECD. http://dx.doi.org/10.1787/health_glance-2013-en
27. Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10(6):428-438, ISSN 1474-1776
28. Panos K, Taylor D, Manning J, Carr M (2010) Implementing value-based pricing for pharmaceuticals in the UK. http://www.2020Health.org
29. PhRMA (2011) Annual report 2011. Technical report, PhRMA. http://www.phrma.org/sites/default/files/159/phrma_2011_annual_report.pdf
30. Towse A, Garrison L (2010) Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products. Pharmacoeconomics 28:93-102. doi:10.2165/11314080-000000000- 00000
31. Zaric GS, O'Brien BJ (2005) Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. Health Econ 14(8):793-803, ISSN 1099-1050. doi:10.1002/hec.976. http://dx.doi.org/10.1002/hec.976
32. Zweifel P, Breyer F, Kifmann M (2009) Health economics, 2nd edn. Springer, Berlin. ISBN 978-3-540-27804-7